Athenex (Athenex) YoY EBITDA Growth : 84.53% (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Athenex YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Athenex's YoY EBITDA Growth for the quarter that ended in Dec. 2022 was 84.53%.

Athenex's EBITDA per Share for the three months ended in Dec. 2022 was $-1.90.

Athenex YoY EBITDA Growth Historical Data

The historical data trend for Athenex's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athenex YoY EBITDA Growth Chart

Athenex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

YoY EBITDA Growth

Get a 7-Day Free Trial

22.41

18.79

4.26

3.38

61.96

Athenex Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
YoY EBITDA Growth	Get a 7-Day Free Trial															-40.57	-18.32	51.27	67.06	84.53

Athenex YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Athenex's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

	YoY EBITDA Growth (A: Dec. 2022 )
=	(EBITDA per Share (A: Dec. 2022 )	-	EBITDA per Share (A: Dec. 2021 ))	/	\| EBITDA per Share (A: Dec. 2021 ) \|
=	(-10.773	-	-28.317)	/	\| -28.317 \|
=	61.96 %

Athenex's YoY EBITDA Growth for the quarter that ended in Dec. 2022 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2022 )
=	(EBITDA per Share (Q: Dec. 2022 )	-	EBITDA per Share (Q: Dec. 2021 ))	/	\| EBITDA per Share (Q: Dec. 2021 )) \|
=	(-1.898	-	-12.269)	/	\| -12.269 \|
=	84.53 %

Athenex YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Athenex's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Athenex (Athenex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (OTCPK:ATNXQ) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203

Website

https://www.athenex.com

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.

Executives

Jinn Wu	director	107 MORGAN LANE, PLAINSBORO NJ 08536
Lau Johnson Yiu Nam	director, officer: CEO and Chairman of the Board
Joe Annoni	officer: Chief Financial Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Timothy Devere Cook	officer: See Remarks	C/O ATHENEX, INC., 1001 MAIN STREET,, SUITE 600, BUFFALO NY 14203
Daniel Lang	officer: Pres Cell Therapy, VP Corp Dev	C/O ATHENEX, INC. CONVENTUS BUILDING, 1001 MAIN ST. STE. 600, BUFFALO NY 14203
Jordan Kanfer	director	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Rudolf Kwan	director, officer: EVP, Chief Medical Officer	C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Michael Smolinski	officer: Chief Scientific Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Steven J. Adams	officer: Interim Chief Acct Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Kim Campbell	director	3300 HYLAND AVE, COSTA MESA CA 92626
William Wei Zuo	officer: President, China	3040 POST OAK BLVD, SUITE 1110, HOUSTON TX 77056
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Manson Fok	director	C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Randoll Sze	officer: Chief Financial Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Stephanie A Davis	director	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203